Propper, David J. http://orcid.org/0000-0002-4274-5460
Gao, Fangfei
Saunders, Mark P.
Sarker, Debashis
Hartley, John A.
Spanswick, Victoria J.
Lowe, Helen L.
Hackett, Louise D.
Ng, Tony T. http://orcid.org/0000-0003-3894-5619
Barber, Paul R.
Weitsman, Gregory E.
Pearce, Sarah
White, Laura
Lopes, Andre
Forsyth, Sharon http://orcid.org/0000-0002-1999-4354
Hochhauser, Daniel http://orcid.org/0000-0001-5522-9281
Funding for this research was provided by:
Cancer Research UK (A15012, A15012, A15012, A15012, A15012)
AstraZeneca (N/A, N/A, N/A, N/A, N/A)
NIHR Biomedical Research Centre - ref: BRC35
Article History
Received: 19 May 2022
Revised: 29 September 2022
Accepted: 4 October 2022
First Online: 9 November 2022
Competing interests
: TTN is Chief Medical Officer of Nano Clinical Ltd. PRB has shares in, and is a consultant for, Nano Clinical Ltd. All other authors declare no conflicts of interest.
: The trial was approved by the National Research Ethics Service Committee: London – Bloomsbury (12/LO/1822), the Medicines and Healthcare Products Regulatory Agency (Clinical Trials Authorisation number 20363/0315/0014-0001), and by the Research and Development department of each participating NHS Trust. The trial was conducted according to the principles of the International Conference on Harmonisation on Good Clinical Practice. All patients gave written informed consent prior to undergoing any trial-specific procedures.
: N/A.